Table 1.
Baseline Characteristics of Patients Enrolled Before (Group A) and After (Group B) Control Strategy of COVID-19 Epidemic
| Characteristic | Group A | Group B | P value |
|---|---|---|---|
| Gender n (%) | 0.774 | ||
| Male | 84(75.0) | 60(73.2) | |
| Female | 28(25.0) | 22(26.8) | |
| Age(years) | 0.606 | ||
| Median(range) | 50.5(18–77) | 50.5(18–71) | |
| Stage n(%) | 0.821 | ||
| I | 5(4.5) | 4(4.9) | |
| II | 10(8.9) | 5(6.1) | |
| III | 42(37.5) | 35(42.7) | |
| IVa | 41(36.6) | 31(37.8) | |
| IVb | 14(12.5) | 7(8.5) | |
| Chemotherapy received n(%) | 100(89.3) | 74(90.2) | 0.828 |
| Karnofsky performance status n(%) | 0.446 | ||
| 70 | 2(1.8) | 0(0) | |
| 80 | 3(2.7) | 3(3.7) | |
| 90 | 107(95.5) | 79(96.3) | |
| Comorbidities n(%) | 32(28.6) | 23(28.0) | 0.936 |
| Patients from other cities n(%) | 75(67.0) | 52(63.4) | 0.608 |
Abbreviation: COVID-19, 2019 novel coronavirus disease.